 SAN DIEGO, May 6, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2021 and recent corporate updates. We are pleased to see the significant progress across our clinical pipeline, including sitravatinib and our novel KRASG12C inhibitor, adagrasib. 